2. Academic Validation
  3. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

  • J Med Chem. 2022 Feb 24;65(4):3123-3133. doi: 10.1021/acs.jmedchem.1c01688.
Xiaolun Wang 1,  Shelley Allen 2,  James F Blake 2,  Vickie Bowcut 1,  David M Briere 1,  Andrew Calinisan 1,  Joshua R Dahlke 2,  Jay B Fell 2,  John P Fischer 2,  Robin J Gunn 1,  Jill Hallin 1,  Jade Laguer 1,  J David Lawson 1,  James Medwid 1,  Brad Newhouse 2,  Phong Nguyen 2,  Jacob M O'Leary 2,  Peter Olson 1,  Spencer Pajk 2,  Lisa Rahbaek 1,  Mareli Rodriguez 2,  Christopher R Smith 1,  Tony P Tang 2,  Nicole C Thomas 1,  Darin Vanderpool 1,  Guy P Vigers 2,  James G Christensen 1,  Matthew A Marx 1
Affiliations

Affiliations

  • 1 Mirati Therapeutics, San Diego, California 92121, United States.
  • 2 Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
PMID: 34889605 DOI: 10.1021/acs.jmedchem.1c01688
Abstract

KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRASG12C, selective inhibition of KRASG12D presents a significant challenge due to the requirement of inhibitors to bind KRASG12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRASG12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRASG12D mutant xenograft mouse tumor model.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-134813
    99.42%, KRAS G12D Inhibitor
    Ras